Lactobacillus salivarius UCC118 Probiotic:
GI Mucosal Adherence & SIBO Symptom Relief

Lactobacillus salivarius UCC118 is a well-characterized and evidence-based probiotic strain. A feeding study led by Fergus Shanahan, MD and his research group at the University College Cork was conducted in ulcerative colitis patients. The results demonstrate the mechanistic evidence for UCC118’s gastrointestinal (GI) transit and adherence to intestinal mucosa

Additionally, a Cleveland Clinic study led by Gail Cresci, PhD, RD demonstrated that daily consumption of the UCC118 probiotic for 3 months helped relieve the severity of GI symptoms associated with small intestinal bacterial overgrowth (SIBO). Learn more about the research supporting L. salivarius UCC118
Fergus Shanahan, MD, DSc is Director of the APC Microbiome Institute at the University College Cork (UCC) in Cork, Ireland, as well as Professor and Chair of the Department of Medicine at UCC. Gail Cresci, PhD, RD is Full Staff in Pediatric Gastroenterology and at the Lerner Research Institute at the Cleveland Clinic, Cleveland, OH
Breastfeeding: The Key to Solving IBD?

“Treat the gut” and “breast is best” are common mantras in the Functional Medicine practitioner’s office. These insights highlight the primary location of foundational imbalance for many chronic illnesses (the gut), as well as potential mechanisms to mitigate these imbalances in the first place (breastfeeding)

Research has shown that human breastmilk confers immunoprotection to the infant gut through various mechanisms, including reducing intestinal permeability and adherence from pathogenic bacteria.  A recent meta-analysis examined whether breastfeeding during infancy was associated with a lower risk of IBD later in life. Thirty-five studies including over 7,500 individuals with IBD and over 330,000 controls were included in the analyses
senior-man-gym.jpg
Can SPM Over-Supplementation Downregulate Endogenous Production?

In this week’s SPM science, Robert Martindale, MD, PhD poses the question: Can over-supplementation of specialized pro-resolving mediators (SPMs) alter the physiology of enzyme pathways , leading to downregulation of endogenous SPM production?

Jesmond Dalli, PhD explains that SPM research has elucidated numerous routes for the removal of these potent mediators, including a Japanese study demonstrating urine excretion of SPMs at biological levels. Therefore, the body’s “on/off switch" , like in endocrine feedback loops and excretion paths, keeps the exogenous/endogenous SPM balance in check
The Difference Between Functional and Personalized Medicine
& The Future of Functional Medicine
Jeffrey Bland, PhD, FACN, FACB, CNS
Thursday, February 22, 2018
11-11:30 AM PT
In the 2nd Metagenics Advanced Practitioner Services (MAPS) talk, Dr. Jeffrey Bland explores “The Difference Between Functional and Personalized Medicine & The Future of Functional Medicine.” As the founder and President of the Personalized Lifestyle Medicine Institute, as well as founder and Chairman Emeritus of The Institute for Functional Medicine, Dr. Bland is uniquely equipped to share the key differences between Functional and personalized medicine. These two approaches to patient care in our healthcare system are not working separately, but together, and are integral to the forward movement of the medical system. Dr. Bland explores the history and more importantly, the future of Functional Medicine
Cutting edge news source inspiring health change through knowledge and education